2024 Q1 Form 10-Q Financial Statement

#000168316824000255 Filed on January 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2022 Q4
Revenue $40.64K $89.44K $0.00
YoY Change
Cost Of Revenue $6.220K
YoY Change
Gross Profit $34.42K
YoY Change
Gross Profit Margin 84.69%
Selling, General & Admin $133.7K $148.9K $283.9K
YoY Change -43.77% -47.54% -57.65%
% of Gross Profit 388.29%
Research & Development $107.2K $112.4K $62.89K
YoY Change 769.57% 78.76% -85.71%
% of Gross Profit 311.45%
Depreciation & Amortization $32.86K $39.46K $43.19K
YoY Change -18.64% -8.62% -16.66%
% of Gross Profit 95.47%
Operating Expenses $240.9K $261.3K $346.8K
YoY Change -3.66% -24.64% -68.77%
Operating Profit -$206.4K -$171.9K -$346.8K
YoY Change -17.43% -50.43% -68.77%
Interest Expense -$119.0K -$6.620K -$10.88K
YoY Change -94.99% -39.15% -94.88%
% of Operating Profit
Other Income/Expense, Net $4.680K -$6.623K -$10.88K
YoY Change -77.7% -39.12% -94.88%
Pretax Income -$325.5K -$178.5K -$357.7K
YoY Change -87.6% -50.09% -72.97%
Income Tax
% Of Pretax Income
Net Earnings -$325.5K -$178.5K -$357.7K
YoY Change -87.6% -50.09% -72.97%
Net Earnings / Revenue -800.84% -199.61%
Basic Earnings Per Share -$0.01 $0.00 -$0.33
Diluted Earnings Per Share -$0.01 $0.00 -$0.33
COMMON SHARES
Basic Shares Outstanding 31.11M shares 28.31M shares 1.258M shares
Diluted Shares Outstanding 30.99M shares 27.76M shares 1.258M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.14K $81.65K $21.60K
YoY Change -22.22% 278.01% -97.25%
Cash & Equivalents $37.14K $81.65K $21.60K
Short-Term Investments
Other Short-Term Assets $126.8K $69.29K $78.09K
YoY Change 107.53% -11.27% -56.17%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $163.9K $150.9K $99.69K
YoY Change 50.61% 51.41% -89.67%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $236.5K $393.6K
YoY Change -100.0% -39.92% -33.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $116.2K
YoY Change -79.39%
Other Assets
YoY Change
Total Long-Term Assets $0.00 $236.5K $509.8K
YoY Change -100.0% -53.62% -55.88%
TOTAL ASSETS
Total Short-Term Assets $163.9K $150.9K $99.69K
Total Long-Term Assets $0.00 $236.5K $509.8K
Total Assets $163.9K $387.4K $609.5K
YoY Change -64.52% -36.44% -71.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $231.4K $245.7K $596.9K
YoY Change -67.44% -58.84% 197.78%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.293M $1.314M $1.763M
YoY Change -16.03% -25.47% 65.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.522M $2.482M $2.584M
YoY Change 1.98% -3.93% 73.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.522M $2.482M $2.584M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.522M $2.482M $2.584M
YoY Change 1.98% -3.93% 73.09%
SHAREHOLDERS EQUITY
Retained Earnings -$24.76M -$24.44M -$20.91M
YoY Change 5.24% 16.89%
Common Stock $3.111K $2.831K $124.00
YoY Change 1301.35% 2183.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.359M -$2.095M -$1.974M
YoY Change
Total Liabilities & Shareholders Equity $163.9K $387.4K $609.5K
YoY Change -64.52% -36.44% -71.25%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$325.5K -$178.5K -$357.7K
YoY Change -87.6% -50.09% -72.97%
Depreciation, Depletion And Amortization $32.86K $39.46K $43.19K
YoY Change -18.64% -8.62% -16.66%
Cash From Operating Activities -$124.4K -$71.85K -$95.92K
YoY Change 571.29% -25.09% -84.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.200K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $20.00K
YoY Change -19.03%
Cash From Investing Activities $20.00K -$1.196K $0.00
YoY Change -19.03% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $24.99K $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -124.4K -$71.85K -$95.92K
Cash From Investing Activities 20.00K -$1.196K $0.00
Cash From Financing Activities 0.000 $24.99K $0.00
Net Change In Cash -104.4K -$48.05K -$95.92K
YoY Change -499.2% -49.9% -84.02%
FREE CASH FLOW
Cash From Operating Activities -$124.4K -$71.85K -$95.92K
Capital Expenditures $0.00 $1.200K
Free Cash Flow -$124.4K -$73.05K
YoY Change 571.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001343009
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-11-30
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
000-52403
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
CNBX PHARMACEUTICALS INC.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5644005
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
#3 Bethesda Metro Center
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2023Q4 dei City Area Code
CityAreaCode
(877)
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
424-2429
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2017289 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
387402 usd
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31111352 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81647 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129696 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
69289 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
94612 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
150936 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
224308 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236466 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
274731 usd
CY2023Q4 us-gaap Assets
Assets
387402 usd
CY2023Q3 us-gaap Assets
Assets
499039 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
245712 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
335915 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1314120 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1343584 usd
CY2023Q4 CNBX Due To Related Party Current
DueToRelatedPartyCurrent
922499 usd
CY2023Q3 CNBX Due To Related Party Current
DueToRelatedPartyCurrent
836829 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2482331 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2516328 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28311352 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28311352 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22611352 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22611352 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2831 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2261 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22339965 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22239652 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24437725 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24259202 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2094929 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
499039 usd
CY2023Q4 us-gaap Revenues
Revenues
89437 usd
CY2022Q4 us-gaap Revenues
Revenues
0 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112418 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62888 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
148919 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
283902 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
261337 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
346790 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-171900 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-346790 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6623 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10879 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2023Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59870 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178523 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-417539 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27760802 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27760802 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1257927 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1257927 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2017289 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34975 usd
CY2023Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
65908 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2094929 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75557 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59870 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1974293 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2023Q4 us-gaap Depreciation
Depreciation
39461 usd
CY2022Q4 us-gaap Depreciation
Depreciation
43185 usd
CY2023Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
11451 usd
CY2022Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
4541 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
34975 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
75557 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-25323 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2687 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4533 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
135784 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71846 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95915 usd
CY2023Q4 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1196 usd
CY2022Q4 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
-0 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1196 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
24993 usd
CY2022Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24993 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-48049 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-95915 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129696 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117515 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81647 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21600 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24437725 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112418 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62888 usd
CY2023Q4 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyHv4zS5S3A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
5700000 shares
CY2023Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
65908 usd
CY2023Q4 CNBX Monthly Operating Lease Expense
MonthlyOperatingLeaseExpense
6500 usd

Files In Submission

Name View Source Status
cnbx-20231130_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001683168-24-000255-index-headers.html Edgar Link pending
0001683168-24-000255-index.html Edgar Link pending
0001683168-24-000255.txt Edgar Link pending
0001683168-24-000255-xbrl.zip Edgar Link pending
cnbx-20231130.xsd Edgar Link pending
cnbx_ex3101.htm Edgar Link pending
cnbx_ex3102.htm Edgar Link pending
cnbx_ex3201.htm Edgar Link pending
cnbx_ex3202.htm Edgar Link pending
cnbx-20231130_def.xml Edgar Link unprocessable
cnbx-20231130_pre.xml Edgar Link unprocessable
cnbx-20231130_lab.xml Edgar Link unprocessable
cnbx_i10q-113023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.jpg Edgar Link pending
image_010.jpg Edgar Link pending
image_011.jpg Edgar Link pending
image_012.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnbx_i10q-113023_htm.xml Edgar Link completed